Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-001 in Chronic Myeloid Leukemia
NCT05304377Phase 1Recruiting
- Sponsor
- Enliven Therapeutics
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 1, open-label trial of relcobatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Enliven Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 3 years and 2 more. Started May 2022; status: recruiting.
02
Drugs
relcobatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05304377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304377.